Vanda Pharmaceuticals | VNDA - Ebitda


Vanda Pharmaceuticals reported $-8.31M in EBITDA for its fiscal quarter ending in December of 2024.





Ebitda Change Date
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD -147.68M 40.33M Jun/2026
AstraZeneca USD 5.16B 510M Jun/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Eli Lilly USD 10.29B 1.86B Mar/2026
Halozyme Therapeutics USD 328.81M 109.24M Jun/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -148.3M 165.88M Mar/2026
J&J USD 8.27B 1.08B Mar/2026
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
Ligand Pharmaceuticals USD -14.3M 81.08M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Moderna USD -1.26B 468M Mar/2026
Novartis USD 5.41B 431M Mar/2026
Pfizer USD 6.01B 18M Jun/2026
PTC Therapeutics USD 61.98M 132.97M Mar/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Sanofi EUR 3.69B 375M Jun/2026
Takeda JPY 364.46B 214.21B Jun/2026
Teva Pharmaceutical Industries USD 474M 581M Jun/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024
Veracyte USD 43.96M 1.16M Jun/2026